|View printer-friendly version|
|St. Jude Medical Announces Launch of 3-D Vessel Reconstruction Technology in Japan|
“The ILUMIEN OPTIS system enables a higher image resolution, and thus
makes it possible for us to analyze difficult anatomical structures,
allowing me to focus on diagnostic and treatment strategies. Also, this
new analytical tool will be helpful for sizing and placing the stent.
This technology has become increasingly important to help efficiently
diagnose and treat patients,” says Dr.
The PressureWire™ Aeris™ Wireless FFR Measurement System collects detailed analyses of blood flow blockages in the coronary vessels to help determine which specific blockages are causing the patient’s blood flow to be ineffective. The FFR pressure guidewire is directed through the coronary arteries and across the narrowed vessel, taking measurements as the guidewire is pulled back through the narrowed part of the artery.
The OCT technology in the new ILUMIEN OPTIS system uses the Dragonfly™ JP Imaging Catheter to capture near-infrared light imaging and measure important vessel characteristics otherwise invisible or difficult to assess with older intracoronary imaging tools. New high resolution setting and real-time, three-dimensional (3-D) reconstruction with the ILUMIEN OPTIS provide a 360-degree panoramic view of the vessel, which makes it easier for physicians to visualize the anatomy they are treating.
The FFR and OCT measurements captured by the ILUMIEN OPTIS system allow physicians to more easily differentiate plaque build-up and determine if the narrowed arteries are causing ischemia, or a restriction in blood flow, ultimately assisting in stent placement. Three-Dimensional representation enables better visualization in preparation for stenting and evaluation of the stent’s position once placed. These advanced functionalities have previously only been available off-line. Three-Dimensional vessel reconstruction offers a better picture, and real-time analysis streamlines workflow, potentially helping physicians diagnose their patients more quickly.
“We are very pleased to offer the ILUMIEN OPTIS system in
The benefits of FFR have been supported in a number of clinical trials, including FAME and FAME 2. The trials effectively demonstrate the important role FFR plays in improving patient care. Results from the original FAME trial found that instances of major adverse cardiovascular events (MACE) were reduced in patients whose treatment was guided by FFR rather than by standard angiography alone. The FAME 2 study revealed the number of patients returning to the hospital for urgent care was 86 percent lower for patients with stable coronary artery disease whose stenting procedure was guided by FFR than for those who received medical therapy alone.
Each year in
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including potential
clinical successes, anticipated regulatory approvals and future product
launches, and projected revenues, margins, earnings and market shares.
The statements made by the Company are based upon management’s current
expectations and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control and the
risk factors and other cautionary statements described in the Company’s
filings with the